CN114945565A - 一种吡咯烷基脲衍生物的晶型及其应用 - Google Patents

一种吡咯烷基脲衍生物的晶型及其应用 Download PDF

Info

Publication number
CN114945565A
CN114945565A CN202180008898.5A CN202180008898A CN114945565A CN 114945565 A CN114945565 A CN 114945565A CN 202180008898 A CN202180008898 A CN 202180008898A CN 114945565 A CN114945565 A CN 114945565A
Authority
CN
China
Prior art keywords
compound
degrees
formula
angles
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180008898.5A
Other languages
English (en)
Inventor
洪绯
陈志亮
王丽菊
林锦霞
蓝文良
张杨
伍文韬
李志祥
秦健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Publication of CN114945565A publication Critical patent/CN114945565A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一种TrkA抑制剂的晶型及其制备方法，并公开了其在制备治疗与疼痛、癌症、炎症、神经变性疾病以及某些感染性疾病等相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180008898.5A 2020-01-10 2021-01-08 一种吡咯烷基脲衍生物的晶型及其应用 Pending CN114945565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010027389 2020-01-10
CN2020100273894 2020-01-10
PCT/CN2021/070956 WO2021139794A1 (zh) 2020-01-10 2021-01-08 一种吡咯烷基脲衍生物的晶型及其应用

Publications (1)

Publication Number Publication Date
CN114945565A true CN114945565A (zh) 2022-08-26

Family

ID=76787764

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008898.5A Pending CN114945565A (zh) 2020-01-10 2021-01-08 一种吡咯烷基脲衍生物的晶型及其应用

Country Status (5)

Country Link
US (1) US11708357B2 (zh)
EP (1) EP4089086A4 (zh)
JP (1) JP7289017B2 (zh)
CN (1) CN114945565A (zh)
WO (1) WO2021139794A1 (zh)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347952B (es) 2011-05-13 2017-05-19 Array Biopharma Inc Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka.
KR101998461B1 (ko) 2014-05-15 2019-07-09 어레이 바이오파마 인크. TrkA 키나제 저해제로서의 1-((3S,4R)-4-(3-플루오로페닐)-1-(2-메톡시에틸)피롤리딘-3-일)-3-(4-메틸-3-(2-메틸피리미딘-5-일)-1-페닐-1H-피라졸-5-일)유레아
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
EP3247692B1 (en) 2015-01-23 2022-09-07 GVK Biosciences Private Limited Inhibitors of trka kinase
EP3330256B1 (en) 2015-07-07 2021-06-16 Shionogi & Co., Ltd. HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
EP3822266A4 (en) * 2018-07-12 2022-04-27 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd PYRROLIDINYL UREA DERIVATIVES AND THEIR USE IN TRKA-RELATED DISEASES

Also Published As

Publication number Publication date
JP7289017B2 (ja) 2023-06-08
US11708357B2 (en) 2023-07-25
WO2021139794A1 (zh) 2021-07-15
EP4089086A1 (en) 2022-11-16
JP2023510826A (ja) 2023-03-15
EP4089086A4 (en) 2023-07-05
US20230103409A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
WO2018045993A1 (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
WO2022171044A1 (zh) 一种氧氮杂螺环化合物、其盐型及其晶型
US20220289722A1 (en) Crystal forms c and e of pyrazin-2(1h)-one compound and preparation method therefor
WO2021023272A1 (zh) 一种atr抑制剂的晶型及其应用
WO2017071607A1 (zh) 4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体
WO2018095345A1 (zh) 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
CN114929701A (zh) 一种pde3/pde4双重抑制剂的结晶及其应用
EP4248966A2 (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
WO2022199591A1 (zh) 一种氟取代的吡啶并吡唑类化合物的晶型及其制备方法
WO2022048545A1 (zh) 一种吡啶并嘧啶化合物的晶型
CN114945565A (zh) 一种吡咯烷基脲衍生物的晶型及其应用
WO2022068860A1 (zh) 一种吡咯并杂环类衍生物的晶型及其制备方法
CA3239813A1 (en) Crystal forms of thienoimidazole compound and preparation method thereof
CN118076614A (zh) 一种egfr抑制剂的多晶型
CN111606888B (zh) 吡咯类衍生物及其制备方法与应用
WO2020164603A1 (zh) 固体形式的fgfr抑制剂化合物及其制备方法
CN114315837A (zh) 一种erk抑制剂的结晶形式及其制备方法
CN116171156A (zh) 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
CN114945568B (zh) 吡咯烷基脲衍生物的制备方法
WO2022048685A1 (zh) 苯并四氢呋喃肟类化合物的晶型及其制备方法
CN113646313B (zh) 一种a2a受体拮抗剂的盐型、晶型及其制备方法
TWI826013B (zh) 咪唑啉酮衍生物的晶型
WO2020224585A1 (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
CN115340502B (zh) Bcl-xl抑制剂及其制备方法和用途
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination